Dal-VESSEL Trial: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==Official Title== A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Me..." |
Rim Halaby (talk | contribs) |
||
| Line 9: | Line 9: | ||
To assess the therapeutic and adverse effects of dalcetrapib on endothelial function, blood pressure, inflammatory markers, and lipid levels in patients with coronary heart disease (CHD) or CHD risk equivalents | To assess the therapeutic and adverse effects of dalcetrapib on endothelial function, blood pressure, inflammatory markers, and lipid levels in patients with coronary heart disease (CHD) or CHD risk equivalents | ||
==Timeline== | |||
==Methods== | |||
==Results== | ==Results== | ||
Revision as of 01:37, 20 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
Dal-VESSEL Trial On the Web |
|
American Roentgen Ray Society Images of Dal-VESSEL Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Official Title
A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents.
Objectives
To assess the therapeutic and adverse effects of dalcetrapib on endothelial function, blood pressure, inflammatory markers, and lipid levels in patients with coronary heart disease (CHD) or CHD risk equivalents